Reexploring 5-methoxyindole-2-carboxylic acid (MICA) as a potential antidiabetic agent

Liang-Jun Yan
Department of Pharmaceutical Sciences, UNT System College of Pharmacy, University of North Texas Health Science Center, Fort Worth, TX, USA

Abstract: 5-Methoxyindole-2-carboxylic acid (MICA) is a potent hypoglycemic agent that inhibits gluconeogenesis in the liver. It is also a well-known inhibitor of mitochondrial dihydrolipoamide dehydrogenase. MICA was extensively studied in the 1960s and 1970s and was once tested for its antidiabetic effect in diabetic Chinese hamsters, whereby MICA was shown to exhibit pronounced glucose-lowering ability while also leading to increased rate of death of the diabetic animals. Since then, MICA's potential ability in lowering blood glucose in diabetes has never been revisited. In my opinion, MICA should be comprehensively reexplored for its antidiabetic properties in a variety of rodent diabetes models. For a given animal model, its dose-dependent effect and the effects of different routes of administrations as well as its synergistic effects with other glucose-lowering drugs should also be investigated. More studies in the future on this chemical may provide novel insights into its role as an antidiabetic agent.

Keywords: 5-methoxyindole-2-carboxylic acid, antidiabetic, diabetes, dihydrolipoamide dehydrogenase, gluconeogenesis, mitochondria

Introduction
Diabetes mellitus, as an insidious disease, has become epidemic and is now a leading health issue globally. This disease is caused by dysregulation of glucose metabolism resulting in persistently high levels of blood glucose that imparts glucotoxicity.1,2 In adult-onset diabetes, also known as type 2 diabetes, development and progression of the disease is initiated by insulin resistance followed by β-cell dysfunction and insulin deficiency.1,3 As type 2 diabetes is a chronic disease that is aging-related, blood glucose control in many patients often requires the use of multipharmacological agents. Hence, there is always a need to develop novel pharmacological agents or chemicals that can be used to help fighting diabetes.

5-methoxyindole-2-carboxylic acid as a hypoglycemic agent
During our studies of mitochondrial dysfunction in stroke injury, we stumbled upon a chemical called 5-methoxyindole-2-carboxylic acid (MICA) (Figure 1), which exhibits a potential role in neuroprotection against stroke injury when applied as either a preconditioning or postconditioning agent.4,5 MICA is often regarded as a biomarker for malignant melanoma,6 but intriguingly, a quick literature search indicates that MICA is actually also a hypoglycemic agent.7,8 In fact, this chemical, having an indole nucleus core structure that is known to possess antidiabetic properties,9,10 was studied...
extensively in 1960s and 1970s in terms of its glucose-lowering ability. It was found that MICA could inhibit liver gluconeogenesis by blocking carboxylation of pyruvate, \(^{11-14}\) a key reaction in the gluconeogenic pathway (Figure 2). The mechanism of this inhibition remains unknown as MICA was found to have no inhibitory effect on purified pyruvate carboxylase when incubated with the enzyme in vitro.\(^ {14}\)

MICA is also able to inhibit aerobic glucose degradation. The mechanism by which this works is that MICA can inhibit mitochondrial dihydrolipoamide dehydrogenase (DLDH)\(^ {14-16}\) a component in the pyruvate dehydrogenase complex\(^ {17,18}\) (Figure 3). This inhibition is reversible and can be reversed by lipoic acid,\(^ {14}\) a cofactor for DLDH. It should be noted that MICA inhibition of the conversion of pyruvate to acetyl-CoA occurs not only just in the liver but also in many other tissues such as adipose, testis, brain, and kidney.\(^ {5,12,19,20}\) The establishment that MICA inhibits DLDH is based on the evidence that the cofactor lipoic acid instead of other cofactors such as thiamine and thiamine pyrophosphate can reverse MICA inhibition of DLDH.\(^ {14}\)

While the concept that MICA can exert its hypoglycemic effect via inhibition of the gluconeogenic pathway is straightforward, whether MICA can decrease blood glucose via inhibition of DLDH remains to be evaluated. Conceptually, when MICA blocks oxidation of pyruvate to acetyl-CoA, pyruvate would accumulate and more glucose would be consumed for ATP production by the glycolytic pathway in order to meet the body's energy needs. This would be similar to one of the mechanisms by which metformin increases glucose consumption by the glycolytic pathway in order to meet the body's energy needs. This would be similar to one of the mechanisms by which metformin increases glucose consumption by the glycolytic pathway in order to meet the body's energy needs. Therefore, MICA may also be able to lower blood glucose by inhibiting DLDH in diabetic subjects.

**MICA's metabolic effects and mortality rate in one diabetic animal model**

The study of MICA's hypoglycemic effect in the 1970s perhaps culminated by a short report that diabetic Chinese hamsters, when treated by MICA (100 mg/kg body weight, via gavage) for approximately a week, showed a depressed blood glucose levels but also died at a greater rate than did control animals.\(^ {22}\) The conclusion of this study was that while MICA could lower blood glucose in diabetic Chinese...
Reexploring MICA as a potential antidiabetic agent

In this review, we propose a reevaluation of MICA and its potential as a hypoglycemic agent. MICA, a potent inhibitor of mitochondrial DLDH, could also lower blood glucose. For a given diabetes model, the hypoglycemic effect of MICA and its toxic effect should be tested with different dosages in combination with different routes of administration. It may also be tested at different dosages with well-known antidiabetic drugs such as metformin and acarbose for its potential synergistic effect. In this regard, its tissue distribution and whether or how it is metabolized in the body should also be investigated.

Additionally, as MICA targets nearly all tissues in the body and has a variety of effects on protein expression and cellular pathways in numerous experimental settings or disease models, its potential effect on pancreatic β-cell function and insulin secretion in the context of diabetes should also be investigated. Moreover, a comprehensive evaluation of MICA on glucose metabolism, in particular, gluconeogenesis in cultured hepatocytes should also be performed.

Finally, it should be noted that in archaeabacterium Haloferax volcanii that lacks lipoic acid in its less complex pyruvate dehydrogenase complex, MICA is a potent inhibitor of the bacterial potassium ion transport and respiration, suggesting that MICA has other biological targets that could bear the toxic brunt of MICA while yielding overall hypoglycemic effects. In fact, in animal models, MICA has been shown to be able to target d-amino acid oxidase, though the inhibitory efficacy is very low. Therefore, it would not be surprising if MICA is found to target other proteins, which may also be implicated for its hypoglycemic function.

Perspectives

Based on the above discussions that MICA is a potent inhibitor of the gluconeogenic pathway in the liver and is also a robust inhibitor of mitochondrial DLDH (as summarized in Figure 4), I think MICA should be further tested in many other rodent models of diabetes for its potential ability in lowering blood glucose. For a given diabetes model, the

Conclusion

MICA, as a potential hypoglycemic agent, should be comprehensively reevaluated using a variety of diabetic animal models. In particular, its effect on mitochondrial bioenergetics, its pharmacokinetics and pharmacodynamics, its adverse effects, and its mechanisms of action on lowering blood glucose should all be studied. Moreover, its synergistic effect, if any, with other antidiabetic drugs, should also be investigated. Additionally, derivatives of MICA exhibiting decreased adverse effects may also be explored. MICA may well be a promising agent for fighting diabetes until proven otherwise.

Acknowledgment

This publication was supported in part by the National Institute of Neurological Disorders and Stroke (Grant number: R01NS079792) and by UNTHSC intramural grants RI10015 and RI10039.

Disclosure

The author reports no conflicts of interest in this work.
References